Cnb Bank Astrazeneca PLC Transaction History

Cnb Bank

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 02, 2023	SELL	$64.85 - $71.7 $6,484 - $7,170	-100 Reduced 45.66%	119 $8,000
Q4 2022 Feb 13, 2023	SELL	$54.21 - $70.44 $4,499 - $5,846	-83 Reduced 27.48%	219 $14,000
Q3 2022 Nov 14, 2022	SELL	$53.02 - $135.75 $2,916 - $7,466	-55 Reduced 15.41%	302 $17,000
Q1 2022 Apr 13, 2022	SELL	$55.72 - $67.12 $12,759 - $15,370	-229 Reduced 39.08%	357 $24,000
Q4 2021 Jan 31, 2022	SELL	$54.02 - $63.83 $22,148 - $26,170	-410 Reduced 41.16%	586 $34,000
Q3 2021 Nov 02, 2021	BUY	$55.56 - $60.79 $49,781 - $54,467	896 Added 896.0%	996 $60,000
Q4 2020 Jan 27, 2021	BUY	$48.52 - $58.02 $4,852 - $5,802	100 New	100 $5,000
Q3 2019 Nov 04, 2019	SELL	$40.12 - $45.47 $33,018 - $37,421	-823 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$37.28 - $41.68 $2,758 - $3,084	-74 Reduced 8.25%	823 $34,000
Q1 2019 Apr 29, 2019	SELL	$35.49 - $43.02 $6,494 - $7,872	-183 Reduced 16.94%	897 $36,000
Q4 2018 Feb 06, 2019	BUY	$36.86 - $41.49 $28,271 - $31,822	767 Added 245.05%	1,080 $41,000
Q2 2018 Aug 14, 2018	BUY	$34.55 - $37.05 $10,814 - $11,596	313 New	313 $25,000

1,334

476M

5.39M

3.75M

Ticker AZN
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 3,099,020,032
Market Cap $221B
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...

Get notified when there are updates to the investment portfolio of Cnb Bank, based on Form 13F filings with the SEC.

Stay updated on Cnb Bank with notifications on news.